--- title: "Bolt Biotherapeutics (BOLT) news: reverse split" url: "https://aibio.space/companies/bolt-biotherapeutics/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "BOLT reverse split, reverse merger, going concern and offering news: Bolt Biotherapeutics sets 1-for-20 reverse stock split, trading adjusted June 9." --- BOLT Bolt Biotherapeutics, Inc. NASDAQ · United States # Bolt Biotherapeutics (BOLT) news BOLT reverse split, reverse merger and going concern news Mergers · 2026-10-23 ## [Bolt Biotherapeutics buys Prana Therapies and raises $120 million](https://aibio.space/news/bolt-biotherapeutics-buys-prana-therapies-raises-120-million/) Bolt Biotherapeutics has agreed to acquire Prana Therapies in a stock-for-stock reverse merger and raise $120 million in a concurrent private placement. After the deal, Bolt's own holders are expected to own about 6.9% of the common stock, and the company says the cash lasts into 2028. ## Latest Bolt Biotherapeutics news 1. 2026-08-11 Company Updates [Bolt Biotherapeutics reports second-quarter results and cash into 2027](https://aibio.space/news/bolt-biotherapeutics-reports-second-quarter-results-cash-2027/) The company had $18.1 million in cash, cash equivalents and marketable securities on June 30, 2026. It expects to report initial clinical data from its lead antibody conjugate, BDC-4182, with its third-quarter results. 2. 2026-05-12 Company Updates [Bolt Biotherapeutics reports first-quarter results and $23.9 million in cash](https://aibio.space/news/bolt-biotherapeutics-reports-first-quarter-results-23-9-million-cash/) The company said its cash should fund operations into 2027, including completion of the dose escalation part of the BDC-4182 study. It expects initial clinical data in the third quarter of 2026. 3. 2025-10-02 Distress [Bolt Biotherapeutics cuts workforce by about 50% and extends cash runway into 2027](https://aibio.space/news/bolt-biotherapeutics-cuts-workforce-about-50-percent-extends-cash/) Bolt will cut about 20 employees, roughly 50% of its workforce, with pre-tax charges of $1.5 million to $2.0 million. The company says the cut extends its cash runway into 2027. Initial BDC-4182 clinical data, now expected in the third quarter of 2026, will come later after a protocol change. 4. 2025-06-06 Listings [Bolt Biotherapeutics sets 1-for-20 reverse stock split, trading adjusted June 9](https://aibio.space/news/bolt-biotherapeutics-sets-1-20-reverse-stock-split-trading-adjusted/) Bolt Biotherapeutics filed a one-for-twenty reverse stock split on June 6, 2025, with split-adjusted trading set for June 9. The 8-K gives no reason for the split, and the company's 2024 annual report already said there was substantial doubt about its ability to continue as a going concern. 5. 2025-06-06 Listings [Bolt Biotherapeutics effects 1:20 reverse stock split](https://aibio.space/news/bolt-biotherapeutics-effects-1-20-reverse-stock-split/) Bolt Biotherapeutics filed a Certificate of Amendment on June 6, 2025 to effect a one-for-twenty reverse stock split. Split-adjusted trading on the Nasdaq Capital Market under the existing ticker BOLT was scheduled to begin June 9, 2025, under a new CUSIP number. ## Bolt Biotherapeutics at a glance - **Ticker**: BOLT - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $17.6 million ### Related companies - [Zevra Therapeutics](https://aibio.space/companies/zevra-therapeutics/) NASDAQ: ZVRA - [Petros Pharmaceuticals](https://aibio.space/companies/petros-pharmaceuticals/) OTC: PTPI - [Palisade Bio](https://aibio.space/companies/palisade-bio/) NASDAQ: PALI - [Spyre Therapeutics](https://aibio.space/companies/spyre-therapeutics/) NASDAQ: SYRE - [Verrica Pharmaceuticals](https://aibio.space/companies/verrica-pharmaceuticals/) NASDAQ: VRCA - [Ionis Pharmaceuticals](https://aibio.space/companies/ionis-pharmaceuticals/) NASDAQ: IONS - [Reviva Pharmaceuticals Holdings](https://aibio.space/companies/reviva-pharmaceuticals/) OTC: RVPH - [Telomir Pharmaceuticals](https://aibio.space/companies/telomir-pharmaceuticals/) NASDAQ: TELO ### Also on NASDAQ - [Disc Medicine](https://aibio.space/companies/disc-medicine/) IRON - [Immix Biopharma](https://aibio.space/companies/immix-biopharma/) IMMX - [Sanara MedTech](https://aibio.space/companies/sanara-medtech/) SMTI - [AC Immune SA](https://aibio.space/companies/ac-immune/) ACIU - [Jin Medical International](https://aibio.space/companies/jin-medical-international/) ZJYL - [Turn Therapeutics](https://aibio.space/companies/turn-therapeutics/) TTRX ## Bolt Biotherapeutics annual financials | Line | FY2025 | FY2024 | |---|---|---| | Revenue | [$7.7 million](https://www.sec.gov/Archives/edgar/data/1641281/000119312526104121/) | [$7.7 million](https://www.sec.gov/Archives/edgar/data/1641281/000119312526104121/) | | Research and development | [$28.5 million](https://www.sec.gov/Archives/edgar/data/1641281/000119312526104121/) | [$57.5 million](https://www.sec.gov/Archives/edgar/data/1641281/000119312526104121/) | | Net income (loss) | [-$33.4 million](https://www.sec.gov/Archives/edgar/data/1641281/000119312526104121/) | [-$63.1 million](https://www.sec.gov/Archives/edgar/data/1641281/000119312526104121/) | | Cash from operations | [-$39.9 million](https://www.sec.gov/Archives/edgar/data/1641281/000119312526104121/) | [-$61.3 million](https://www.sec.gov/Archives/edgar/data/1641281/000119312526104121/) | | Cash and equivalents | [$11.7 million](https://www.sec.gov/Archives/edgar/data/1641281/000119312526344597/) | [$7.2 million](https://www.sec.gov/Archives/edgar/data/1641281/000119312526104121/) | | Short-term investments | [$15.8 million](https://www.sec.gov/Archives/edgar/data/1641281/000119312526344597/) | [$40.1 million](https://www.sec.gov/Archives/edgar/data/1641281/000119312526104121/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $12.9 million, plus short-term investments of $4.7 million, $17.6 million in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Bolt Biotherapeutics Did Bolt Biotherapeutics do a reverse stock split? Our latest story on this, dated Jun 6, 2025: "Bolt Biotherapeutics sets 1-for-20 reverse stock split, trading adjusted June 9". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/bolt-biotherapeutics-sets-1-20-reverse-stock-split-trading-adjusted/). Is Bolt Biotherapeutics doing a reverse merger? Our latest story on this, dated Oct 23, 2026: "Bolt Biotherapeutics buys Prana Therapies and raises $120 million". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/bolt-biotherapeutics-buys-prana-therapies-raises-120-million/). Has Bolt Biotherapeutics issued a going-concern warning? Our latest story on this, dated Jun 6, 2025: "Bolt Biotherapeutics sets 1-for-20 reverse stock split, trading adjusted June 9". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/bolt-biotherapeutics-sets-1-20-reverse-stock-split-trading-adjusted/). Has Bolt Biotherapeutics raised money recently? Our latest story on this, dated Oct 23, 2026: "Bolt Biotherapeutics buys Prana Therapies and raises $120 million". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/bolt-biotherapeutics-buys-prana-therapies-raises-120-million/). What is the ticker symbol of Bolt Biotherapeutics? Bolt Biotherapeutics, Inc. trades under the ticker BOLT on NASDAQ. Where is Bolt Biotherapeutics listed? Bolt Biotherapeutics, Inc. is listed on NASDAQ. What is the SEC CIK of Bolt Biotherapeutics? The SEC Central Index Key (CIK) for Bolt Biotherapeutics, Inc. is 1641281. Its filings are on SEC EDGAR. How many shares does Bolt Biotherapeutics have outstanding? 1,926,345 shares as of 2026-08-04, per the cover page of its 10-Q filed 2026-08-11. Which country or territory is Bolt Biotherapeutics listed under? Our directory records Bolt Biotherapeutics, Inc. under United States. What does Bolt Biotherapeutics do? Our directory classifies Bolt Biotherapeutics, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of Bolt Biotherapeutics? The ISIN recorded for Bolt Biotherapeutics, Inc. is US0977022039. Does aibio.space cover Bolt Biotherapeutics? aibio.space lists Bolt Biotherapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Bolt Biotherapeutics incorporated? SEC records list its state or country of incorporation as DE. What was Bolt Biotherapeutics's revenue last year? $7.7 million for the fiscal year ended Dec 31, 2025, as reported to the SEC. Is Bolt Biotherapeutics profitable? Bolt Biotherapeutics, Inc. reported a net loss of $33.4 million for the fiscal year ended Dec 31, 2025, and used $39.9 million of cash in operations, per its annual report to the SEC. ## Investor discussion: Bolt Biotherapeutics Members talk about Bolt Biotherapeutics (BOLT). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Bolt Biotherapeutics, newest first. Each line links the filing it comes from. 1. 2026-10-23 Mergers Reported a merger or acquisition agreement. SEC Form 8-K (Items 1.01,1.02,2.01,3.02,5.02,5.03,7.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1641281/000119312526429647/bolt-ex99_1.htm) 2. 2026-04-28 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/1641281/000119312526186923/bolt-20260424.htm) 3. 2026-03-12 Legal Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1641281/000119312526104121/bolt-20251231.htm) 4. 2025-10-02 Distress Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 2.05,8.01). [Source](https://www.sec.gov/Archives/edgar/data/1641281/000119312525228293/bolt-ex99_1.htm) 5. 2025-06-06 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,5.03). [Source](https://www.sec.gov/Archives/edgar/data/1641281/000095017025083180/bolt-20250606.htm) 6. 2025-06-04 Listings Reported a reverse stock split. SEC Form 8-K (Items 8.01). [Source](https://www.sec.gov/Archives/edgar/data/1641281/000095017025081607/bolt-20250604.htm) 7. 2025-05-28 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). [Source](https://www.sec.gov/Archives/edgar/data/1641281/000095017025077880/bolt-20250527.htm) 8. 2025-04-25 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/1641281/000095017025058632/bolt-20250425.htm) 9. 2025-04-15 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/1641281/000095017025054294/2025_bolt_def_14a.htm) 10. 2025-03-24 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1641281/000095017025043873/bolt-20241231.htm) 11. 2025-01-03 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1641281/000095017025001159/bolt-20250102.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:BOLT on TradingView](https://www.tradingview.com/symbols/NASDAQ-BOLT/). ## SEC filings and registration - **SEC name**: Bolt Biotherapeutics, Inc. - **CIK**: 1641281 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: BOLT (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**:
Emerging growth company - **Business address**: 900 CHESAPEAKE DRIVE, REDWOOD CITY, CA, 94063 - **Phone**: 650-665-9295 - **Shares outstanding**: 1,926,345 as of 2026-08-04 (10-Q filed 2026-08-11) - **Former names**: Bolt Therapeutics, Inc. ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1641281/000119312526415560/bolt-20261001.htm) filed 2026-10-06 - [10-Q](https://www.sec.gov/Archives/edgar/data/1641281/000119312526344597/bolt-20260630.htm) filed 2026-08-11 - [8-K](https://www.sec.gov/Archives/edgar/data/1641281/000119312526344580/bolt-20260811.htm) filed 2026-08-11 - [8-K](https://www.sec.gov/Archives/edgar/data/1641281/000119312526267487/bolt-20260611.htm) filed 2026-06-11 - [10-Q](https://www.sec.gov/Archives/edgar/data/1641281/000119312526219382/bolt-20260331.htm) filed 2026-05-12 - [8-K](https://www.sec.gov/Archives/edgar/data/1641281/000119312526219361/bolt-20260512.htm) filed 2026-05-12 - [DEF 14A](https://www.sec.gov/Archives/edgar/data/1641281/000119312526186923/bolt-20260424.htm) filed 2026-04-28 - [10-K](https://www.sec.gov/Archives/edgar/data/1641281/000119312526104121/bolt-20251231.htm) filed 2026-03-12 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001641281), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Bolt Biotherapeutics, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker BOLT, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Bolt Biotherapeutics, Inc. - **Ticker**: BOLT - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Pharmaceuticals: Major - **ISIN**: US0977022039 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-BOLT/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/bolt-biotherapeutics/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Bolt Biotherapeutics (BOLT) news: reverse split", 2026-10-31, https://aibio.space/companies/bolt-biotherapeutics/